| Full text | |
| Author(s): |
de Sa, Vanessa Karen
[1]
;
Olivieri, Eloisa
[2]
;
Parra, Edwin Roger
[1]
;
Ab'Saber, Alexandre Muxfeldt
[1]
;
Takagaki, Teresa
[3]
;
Soares, Fernando Augusto
[2]
;
Carraro, Dirce
[2]
;
Carvalho, Lina
[4]
;
Capelozzi, Vera Luiza
[1]
Total Authors: 9
|
| Affiliation: | [1] Univ Sao Paulo, Fac Med, Dept Pathol, BR-01246903 Sao Paulo - Brazil
[2] Hosp Canc AC Camargo, BR-01509010 Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Discipline Oncol, BR-01246903 Sao Paulo - Brazil
[4] Univ Coimbra, Fac Med, Inst Anat Patol, P-3004504 Coimbra - Portugal
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | HUMAN PATHOLOGY; v. 43, n. 5, p. 675-683, MAY 2012. |
| Web of Science Citations: | 11 |
| Abstract | |
Heterogeneity of hyaluronidase (HYAL) expression has been identified in tumors and shows promise as an indicator of disease progression. The expression profile of alternatively spliced forms of HYAL was evaluated in tumors and normal lung tissue from 69 resected tumors of patients with adenocarcinomas and squamous cell carcinomas. HYAL1-wild-type (wt) and variants 1 to 5, HYAL2-wt, and HYAL3-wt, and variants 1 to 3 were identified by polymerase chain reaction and direct sequencing. Different proportions of the 3 HYAL-wt and variants were expressed in tumor and normal lung tissues. HYAL1-wt was associated with a poorer prognosis and HYAL3-vl with a better prognosis. HYAL splice variants are associated with histology and outcome, suggesting that strategies aimed at modulating their levels may be effective for lung cancer treatment. (C) 2012 Elsevier Inc. All rights reserved. (AU) | |